Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers.
HBV
HIV
anti-HBc titer
anti-HBs titer
droplet digital PCR
serum HBV-DNA
serum HBV-RNA
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
received:
15
10
2020
revised:
09
11
2020
accepted:
17
11
2020
entrez:
21
11
2020
pubmed:
22
11
2020
medline:
22
11
2020
Statut:
epublish
Résumé
The anti-HBc-positive/HBsAg-negative status is frequent in HIV-infection and correlates with poor survival. Here, by highly-sensitive assays, we evaluate cryptic HBV replication and factors correlated with its detection in 81 anti-HBc-positive/HBsAg-negative HIV-infected patients. Patients were treated for >12 months with HBV-active modern combined antiretroviral-therapy (cART) and had serum HBV-DNA < 20 IU/mL by commercial Real-Time PCR. Serum HBV-DNA was quantified by droplet digital PCR, serum HBV-RNA by an Abbott research assay, and anti-HBc titer (proposed to infer intrahepatic cccDNA) by Lumipulse/Fujirebio. Cryptic serum HBV-DNA was detected in 29.6% of patients (median (IQR): 4(1-15) IU/mL) and serum HBV-RNA in 3.7% of patients despite HBsAg-negativity and HBV-active cART. Notably, cryptic serum HBV-DNA correlated with an advanced CDC-stage (
Identifiants
pubmed: 33218205
pii: microorganisms8111819
doi: 10.3390/microorganisms8111819
pmc: PMC7699270
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Med Virol. 2007 Oct;79(10):1464-71
pubmed: 17705185
Curr HIV/AIDS Rep. 2018 Apr;15(2):172-181
pubmed: 29572624
J Med Virol. 2018 Feb;90(2):291-303
pubmed: 28971485
Transfus Clin Biol. 2004 Feb;11(1):18-25
pubmed: 14980545
Clin Microbiol Infect. 2015 Feb;21(2):197-203
pubmed: 25658546
J Hepatol. 2020 Oct;73(4):952-964
pubmed: 32504662
Bull Math Biol. 2005 Nov;67(6):1227-51
pubmed: 16023709
World J Hepatol. 2014 Dec 27;6(12):860-9
pubmed: 25544873
Open Forum Infect Dis. 2018 Oct 05;5(10):ofy251
pubmed: 30377627
J Hepatol. 2018 Aug;69(2):301-307
pubmed: 29621551
Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195
pubmed: 29062862
Clin Mol Hepatol. 2020 Jul;26(3):261-279
pubmed: 32536045
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
J Clin Med. 2020 Jan 11;9(1):
pubmed: 31940817
J Med Virol. 2010 Feb;82(2):206-12
pubmed: 20029819
J Infect Dis. 2016 Jun 1;213(11):1735-42
pubmed: 26768256
AIDS. 2012 Sep 10;26(14):1755-63
pubmed: 22614885
J Cancer. 2013 Jul 11;4(6):473-80
pubmed: 23901347
J Viral Hepat. 2020 Mar;27(3):294-315
pubmed: 31603999
Oncotarget. 2017 Feb 14;8(7):11063-11070
pubmed: 28052021
J Med Virol. 2009 Mar;81(3):441-5
pubmed: 19152397
Hepatology. 2018 Dec;68(6):2106-2117
pubmed: 29734472
Infection. 2009 Oct;37(5):445-9
pubmed: 19669092
J Hepatol. 2017 Feb;66(2):460-462
pubmed: 27826059
AIDS. 2017 Sep 24;31(15):2035-2052
pubmed: 28692539
World J Gastroenterol. 2014 May 28;20(20):5951-61
pubmed: 24876718
PLoS One. 2015 Jun 26;10(6):e0130209
pubmed: 26115521
Sci Rep. 2019 Aug 16;9(1):11942
pubmed: 31420570
J Infect Chemother. 2020 Jan;26(1):28-32
pubmed: 31279522
PLoS One. 2018 Jan 9;13(1):e0190592
pubmed: 29315352
J Hepatol. 2008 Oct;49(4):652-7
pubmed: 18715666
Viruses. 2019 Nov 19;11(11):
pubmed: 31752284
J Chin Med Assoc. 2018 Dec;81(12):1052-1059
pubmed: 30143430
J Hepatol. 2016 Oct;65(4):700-710
pubmed: 27245431
Antiviral Res. 2019 Sep;169:104553
pubmed: 31288041
Clin Infect Dis. 2020 Jul 20;:
pubmed: 32687164
J Acquir Immune Defic Syndr. 2016 May 1;72(1):e14-7
pubmed: 26829660